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Correlations Between Management Behaviors and Financial Indicators 
with FDA Compliance Leading to Medicine Shortages
Francisco Gutiérrez-Pérez, PhD
Abstract
A series of Food and Drug Administration (FDA) 
interventions and enforcement actions against 
pharmaceutical manufacturers in the past 5-6 years 
led to medicine shortages in the United States. 
• The manufacturing shortfalls made essential 
medicines unavailable for the treatment of patients.
• Manufacturing shortfalls implied that quality 
management and manufacturing systems were not 
empowered or adequately staffed to support the 
critical functions of the pharmaceutical firms.
Procedures
I selected to conduct a quantitative study. 
• correlations
• regression line analyses
Study Variables 
• Independent Variables: Management Behaviors and       
Financial Indicators
• Dependent Variable: Compliance with FDA 
Regulations
• Treatment: FDA Intervention
• Scenarios: Pre-FDA and Post-FDA Intervention
Participants
• 1144 members of the International Society of 
Pharmaceutical Engineers (ISPE) with job titles 
representing management positions.
• Participants from public pharmaceutical companies 
in the United States. 
Data Collection
The complete responses from 21 participants through 
133 Likert-type scales and scaled ranges were the 
input to the data analysis.
Data Analysis
Correlations, aggregate comparison and Cronbach’s 
alpha were utilized. ANOVA, t tests, Durbin-Watson 
statistics, and collinearity statistics supported the 
examination of the assumptions to establish the 
generalization of the findings.
Research Questions
RQ 1:  To what extent, if any, do management 
behaviors correlate to compliance with FDA 
regulations at the pharmaceutical firms in the USA?
RQ 2:  To what extent, if any, do financial indicators 
correlate to compliance with FDA regulations at the 
pharmaceutical firms in the USA?
RQ 3:  To what extent, if any, do financial indicators 
impact compliance with FDA regulations at the 
pharmaceutical firms in the USA?
Problem
The general problem investigated in this study was a 
significant increase in the number of pharmaceutical 
firms cited for noncompliance with federal quality 
guidelines.
• In the first three years of the Obama Administration, 
the number of warning letters issued to 
pharmaceutical firms for manufacturing and quality 
problems increased to 49 letters. (Nguyen, Seoane-
Vazquez, Rodriguez-Monguio, & Montagne, 2013).
• In comparison, the FDA only issued nine warning 
letters in the last three years of the George W. Bush 
Administration (Nguyen, Seoane-Vazquez, 
Rodriguez-Monguio, & Montagne, 2013). 
• In a letter dated October 31, 2011, the FDA 
indicated that about 54% of drug shortages were a 
result of manufacturers’ quality issues (FDA, 2011). 
• The lack of compliance with Current Good 
Manufacturing Practices (CGMP) led to 
pharmaceuticals manufacturing facility closures, 
loss of revenues, certain penalty fees, loss of 
reputation, and significant investments to address 
remediation of their non-conformances to the FDA 
regulations. (Asotra, Cossin, & Yacobi, 2012). 
Relevant Literature
• The level of sustainability depends on the degree of 
change that management embraces and accepts 
(Asotra, Cossin, & Yacobi, 2012).  
• As emphasized by Woodcock (2012), manufacturing 
shortfalls implied that quality management and 
systems were not empowered or properly staffed. 
• Historical trends of drug shortages represented an 
increase from 61 shortages in 2005 (Barlas, 2014) 
to 251 shortages in 2011 (FDA, 2013).
Theoretical Framework
The theory of planned behavior (TPB) was used to 
frame the behaviors of the pharmaceutical managers 
(Ajzen, 1991). 
• Central point of TPB -- a direct relationship between 
intention and actual behavior.
• TPB highlights -- behavior could be explained and 
behaviors are not difficult to predict. 
For this study, the intention of management to comply 
with the regulations of the FDA, as well as with the 
financial limitations, created an excellent scenario to 
examine with the TPB. Social Change Implications
• The main potential social impact was to avoid 
having medicine shortages.
• The risk of affecting the patient health could be 
minimized or eliminated by avoiding medicine  
shortages. 
• The study was directed to encourage managers of 
pharmaceutical organizations to operate and 
behave with a clear approach to compliance. 
Limitations
• Only 21 out of 1144 ISPE invitees completed the 
survey, possibly due to apathy for surveys, internet 
firewalls, and the sensitivity of the topic of 
compliance in the pharmaceutical industry.  




Having a high level of compliance with the FDA 
regulations reduces investments and compliance 
expenses minimizing interruptions in the supply of 
essential pharmaceutical drugs.  
Stockholders
The significant correlation between stockholders’ 
equity and compliance, in both pre-FDA and post-
FDA interventions, signaled the relevance of the 
firm’s compliance and the investors’ expectations. 
Management
The behaviors and the decision-making processes 
of the pharmaceutical manager could reinforce the 
presence of effective quality systems eliminating or 
minimizing medicine shortages.
Pharmaceutical Firm
The lack of compliance could impact the reputation 
and the performance of the firm negatively.
Findings
• The FDA intervention had a favorable influence on 
the participants’ behaviors increasing the level of 
compliance.
• The TPB provided linear regression models to 
predict behavior reinforcing that management could 
modify behaviors to enhance future compliance.
• Behaviors and financial indicators correlated with 
compliance of the firm with the FDA regulations.  
• The financial indicators contributed to the impact on 
compliance in the regression model only during the 
Pre-FDA intervention.
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Purpose
Determine to what extent, if any, management 
behavior and financial indicators were correlated with 
the compliance of FDA regulations leading to medicine 
shortages. 
